clinical_trial 1,227 words KG: ent-clin-c6f868f2 2026-03-27
parkinson-diseaseclinical-trialantioxidantglutathioneneuroprotectionphase-1gamma-glutamylcysteinenct07064005
Contents

GGC/Glutathione Antioxidant Enrichment for Parkinson's Disease (NCT07064005)

Knowledge Graph

Related Hypotheses (3)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Extracellular Matrix Stiffness Modulation
Score: 0.43

Related Analyses (13)

What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed

Related Experiments (30)

Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40